Uncontrolled Wet AMD: Drug Switch Can Mute Disease Activity

Phase 3 data from the 2023 ARVO meeting showed treatment with the monoclonal antibody improved visual acuity in some patients.

Related Keywords

Australia ,Paris ,France General ,France ,Sydney ,New South Wales ,Australian ,Ramin Tadayoni ,Mark Gillies ,Brolucizumab Beovu ,Iveric Bio ,Srinivasr Sadda ,Doheny Eye Institute ,Genentech ,University Of Paris ,Association For Research ,Macula Research Group ,Novartis ,Allergan ,University Of Sydney Save Sight Institute ,Saint Louis University Hospitals ,California Los Angeles David Geffen School ,Drug Administration ,Sydney Save Sight ,Exudative Age Related Macular Degeneration ,Xudative Armd ,Vision Care And Maintenance ,Epimacular Membrane ,Macular Dystrophy ,Macular Amyloidosis ,Visual Acuity ,Drug Development ,Vegf Vascular Endothelial Growth Factor ,Vascular Endothelial Growth Factor ,Ascular Endothelial Growth Factor Vegf ,Vegf Inhibitor ,Vascular Endothelial Growth Factor Inhibitor ,Biologic Therapy ,Vasculitis ,Intraocular In ,